A vs. ISRG: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at A and ISRG, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ISRG’s market capitalization of 195.15 billion USD is significantly greater than A’s 34.48 billion USD, highlighting its more substantial market valuation.
With betas of 1.23 for A and 1.68 for ISRG, both stocks show similar sensitivity to overall market movements.
| Symbol | A | ISRG |
|---|---|---|
| Company Name | Agilent Technologies, Inc. | Intuitive Surgical, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Diagnostics & Research | Medical - Instruments & Supplies |
| CEO | Padraig McDonnell | Gary S. Guthart |
| Price | 121.38 USD | 544.47 USD |
| Market Cap | 34.48 billion USD | 195.15 billion USD |
| Beta | 1.23 | 1.68 |
| Exchange | NYSE | NASDAQ |
| IPO Date | November 18, 1999 | June 16, 2000 |
| ADR | No | No |
Historical Performance
This chart compares the performance of A and ISRG by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
A
19.46%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
In the upper quartile for the Medical - Diagnostics & Research industry, A’s Return on Equity of 19.46% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
ISRG
15.52%
Medical - Instruments & Supplies Industry
- Max
- 26.65%
- Q3
- 13.00%
- Median
- 1.08%
- Q1
- -8.11%
- Min
- -38.20%
In the upper quartile for the Medical - Instruments & Supplies industry, ISRG’s Return on Equity of 15.52% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
A
11.71%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
In the upper quartile for the Medical - Diagnostics & Research industry, A’s Return on Invested Capital of 11.71% signifies a highly effective use of its capital to generate profits when compared to its peers.
ISRG
12.36%
Medical - Instruments & Supplies Industry
- Max
- 20.14%
- Q3
- 7.36%
- Median
- 1.97%
- Q1
- -6.22%
- Min
- -20.00%
In the upper quartile for the Medical - Instruments & Supplies industry, ISRG’s Return on Invested Capital of 12.36% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
A
17.59%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
A Net Profit Margin of 17.59% places A in the upper quartile for the Medical - Diagnostics & Research industry, signifying strong profitability and more effective cost management than most of its peers.
ISRG
28.41%
Medical - Instruments & Supplies Industry
- Max
- 28.95%
- Q3
- 11.24%
- Median
- -2.83%
- Q1
- -12.85%
- Min
- -26.41%
A Net Profit Margin of 28.41% places ISRG in the upper quartile for the Medical - Instruments & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
A
21.38%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
An Operating Profit Margin of 21.38% places A in the upper quartile for the Medical - Diagnostics & Research industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
ISRG
28.20%
Medical - Instruments & Supplies Industry
- Max
- 32.10%
- Q3
- 16.03%
- Median
- 2.28%
- Q1
- -7.96%
- Min
- -26.84%
An Operating Profit Margin of 28.20% places ISRG in the upper quartile for the Medical - Instruments & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | A | ISRG |
|---|---|---|
| Return on Equity (TTM) | 19.46% | 15.52% |
| Return on Assets (TTM) | 9.59% | 12.88% |
| Return on Invested Capital (TTM) | 11.71% | 12.36% |
| Net Profit Margin (TTM) | 17.59% | 28.41% |
| Operating Profit Margin (TTM) | 21.38% | 28.20% |
| Gross Profit Margin (TTM) | 53.79% | 67.09% |
Financial Strength
Current Ratio
A
2.09
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
A’s Current Ratio of 2.09 aligns with the median group of the Medical - Diagnostics & Research industry, indicating that its short-term liquidity is in line with its sector peers.
ISRG
4.98
Medical - Instruments & Supplies Industry
- Max
- 6.79
- Q3
- 4.57
- Median
- 2.64
- Q1
- 1.81
- Min
- 1.10
ISRG’s Current Ratio of 4.98 is in the upper quartile for the Medical - Instruments & Supplies industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio
A
0.57
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
A’s Debt-to-Equity Ratio of 0.57 is typical for the Medical - Diagnostics & Research industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ISRG
--
Medical - Instruments & Supplies Industry
- Max
- 1.46
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.16
- Min
- 0.03
Debt-to-Equity Ratio data for ISRG is currently unavailable.
Interest Coverage Ratio
A
-472.33
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
A has a negative Interest Coverage Ratio of -472.33. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
ISRG
--
Medical - Instruments & Supplies Industry
- Max
- 25.04
- Q3
- 8.80
- Median
- 3.66
- Q1
- -3.85
- Min
- -11.93
Interest Coverage Ratio data for ISRG is currently unavailable.
Financial Strength at a Glance
| Symbol | A | ISRG |
|---|---|---|
| Current Ratio (TTM) | 2.09 | 4.98 |
| Quick Ratio (TTM) | 1.60 | 3.97 |
| Debt-to-Equity Ratio (TTM) | 0.57 | -- |
| Debt-to-Asset Ratio (TTM) | 0.29 | -- |
| Net Debt-to-EBITDA Ratio (TTM) | 1.43 | -0.87 |
| Interest Coverage Ratio (TTM) | -472.33 | -- |
Growth
The following charts compare key year-over-year (YoY) growth metrics for A and ISRG. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
A
0.81%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.81%, A offers a more attractive income stream than most of its peers in the Medical - Diagnostics & Research industry, signaling a strong commitment to shareholder returns.
ISRG
0.00%
Medical - Instruments & Supplies Industry
- Max
- 4.02%
- Q3
- 0.38%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ISRG currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
A
23.76%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
A’s Dividend Payout Ratio of 23.76% is in the upper quartile for the Medical - Diagnostics & Research industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
ISRG
0.00%
Medical - Instruments & Supplies Industry
- Max
- 76.77%
- Q3
- 11.37%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ISRG has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | A | ISRG |
|---|---|---|
| Dividend Yield (TTM) | 0.81% | 0.00% |
| Dividend Payout Ratio (TTM) | 23.76% | 0.00% |
Valuation
Price-to-Earnings Ratio
A
29.67
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
A’s P/E Ratio of 29.67 is within the middle range for the Medical - Diagnostics & Research industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ISRG
78.61
Medical - Instruments & Supplies Industry
- Max
- 45.65
- Q3
- 44.10
- Median
- 35.47
- Q1
- 29.60
- Min
- 21.65
At 78.61, ISRG’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Medical - Instruments & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Forward P/E to Growth Ratio
A
3.80
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
A Forward PEG Ratio of 3.80 places A in the upper quartile for the Medical - Diagnostics & Research industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
ISRG
4.99
Medical - Instruments & Supplies Industry
- Max
- 5.80
- Q3
- 3.68
- Median
- 2.56
- Q1
- 1.87
- Min
- 0.22
A Forward PEG Ratio of 4.99 places ISRG in the upper quartile for the Medical - Instruments & Supplies industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
Price-to-Sales Ratio
A
5.20
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
A’s P/S Ratio of 5.20 aligns with the market consensus for the Medical - Diagnostics & Research industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
ISRG
22.39
Medical - Instruments & Supplies Industry
- Max
- 12.87
- Q3
- 6.95
- Median
- 3.45
- Q1
- 2.24
- Min
- 0.71
With a P/S Ratio of 22.39, ISRG trades at a valuation that eclipses even the highest in the Medical - Instruments & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio
A
5.64
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
ISRG
11.38
Medical - Instruments & Supplies Industry
- Max
- 9.60
- Q3
- 5.48
- Median
- 3.37
- Q1
- 1.95
- Min
- 0.65
At 11.38, ISRG’s P/B Ratio is at an extreme premium to the Medical - Instruments & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | A | ISRG |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 29.67 | 78.61 |
| Forward PEG Ratio (TTM) | 3.80 | 4.99 |
| Price-to-Sales Ratio (P/S, TTM) | 5.20 | 22.39 |
| Price-to-Book Ratio (P/B, TTM) | 5.64 | 11.38 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 24.63 | 111.81 |
| EV-to-EBITDA (TTM) | 25.95 | 65.25 |
| EV-to-Sales (TTM) | 5.51 | 22.10 |